Alzheimer's Disease Nrf2-Keap1 Pathway and Oxidative Stress Therapy Companies

AD NRF2-KEAP1 Oxidative Stress Therapy Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing Nrf2 activators, Keap1 inhibitors, antioxidant response element (ARE) modulators, and oxidative stress reduction therapies for Alzheimer's disease. The [Nrf2-Keap1 pathway](/mechanisms/nrf2-keap1-pathway) is the primary cellular defense mechanism against oxidative stress, a core pathological hallmark of Alzheimer's disease. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection against amyloid-beta and tau toxicity.

Companies targeting this pathway aim to restore redox homeostasis in the AD brain, addressing a fundamental upstream driver of neurodegeneration rather than downstream amyloid or tau pathology alone[@nrf2_sig].

Pathway / Mechanism Diagram

AD NRF2-KEAP1 Oxidative Stress Therapy Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing Nrf2 activators, Keap1 inhibitors, antioxidant response element (ARE) modulators, and oxidative stress reduction therapies for Alzheimer's disease. The [Nrf2-Keap1 pathway](/mechanisms/nrf2-keap1-pathway) is the primary cellular defense mechanism against oxidative stress, a core pathological hallmark of Alzheimer's disease. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection against amyloid-beta and tau toxicity.

Companies targeting this pathway aim to restore redox homeostasis in the AD brain, addressing a fundamental upstream driver of neurodegeneration rather than downstream amyloid or tau pathology alone[@nrf2_sig].

Pathway / Mechanism Diagram

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Direct Nrf2 Activators | Bind KEAP1 cysteine residues to release Nrf2 | Reata/Alnylam, Biogen, Nacuity |
| Keap1 Inhibitors | Disrupt Keap1-Nrf2 binding to free Nrf2 | Evotec, academia spinouts |
| ARE Modulators | Modulate antioxidant response element transcription | Various research-stage |
| Oxidative Stress Reducers | Scavenge ROS, support glutathione pathways | Cyclo Therapeutics, Pfizer |
| Mitochondrial Nrf2 | Target Nrf2 to improve mitochondrial function | Indus Therapeutics |
| Combination Approaches | Nrf2 + anti-inflammatory or metabolic targets | Oryzon Genomics, Alector |

Nrf2 Activator Companies

Reata Pharmaceuticals (acquired by Alnylam)

• Focus: Nrf2 activation for AD and other neurodegenerative conditions
• Lead Candidate: Bardoxolone methyl (omaveloxolone variant)
• Mechanism: Covalently binds KEAP1 cysteine residues, releasing Nrf2 to translocate to the nucleus and activate ARE-driven gene expression
• Indication: Alzheimer's disease
• Stage: Phase 2
• Notes: Acquired by Alnylam in 2023. Bardoxolone methyl derivative (omaveloxolone) approved for Friedreich's ataxia. AD program leverages same Nrf2 activation mechanism with optimized CNS penetration strategy[@bardoxolone_ct]
• Key Targets: HO-1 (heme oxygenase-1), NQO1, GCL (glutamate-cysteine ligase), GSTA2

Biogen

• Focus: Repurposing approved Nrf2 activators for neurodegeneration
• Lead Candidate: Dimethyl fumarate (Tecfidera)
• Mechanism: Nrf2 activator through KEAP1 modification; also has immunomodulatory effects through HCA2 receptor
• Indication: Alzheimer's disease, ALS
• Stage: Phase 3 (ALS), Phase 2 (AD)
• Notes: Already approved for multiple sclerosis. DIMSUM trial investigated dimethyl fumarate in early AD. Multiple mechanisms beyond Nrf2 including neuroprotection via HCA2 and modulation of gut immune axis
• Clinical Trials: DIMSUM (dimethyl fumarate for AD), Fumarate extension studies

Nacuity Pharmaceuticals

• Focus: Nrf2 activator for retinitis pigmentosa and neurodegenerative diseases
• Lead Candidate: NPI-001
• Mechanism: Nrf2 activator with potential for CNS and retinal applications; targets oxidative stress through ARE upregulation
• Indication: Alzheimer's disease (preclinical), retinitis pigmentosa (Phase 2)
• Stage: Phase 2 (RP), preclinical (AD)
• Notes: Australian biotech with Nrf2 platform. Strong scientific basis for AD applications given role of oxidative stress in neurodegeneration

Keap1 Inhibitor Companies

Evotec

• Focus: Drug discovery partnerships and Keap1/Nrf2 modulator development
• Mechanism: High-throughput screening for Keap1 inhibitors; partnered programs with pharma
• Indication: Alzheimer's disease, metabolic diseases
• Stage: Research/collaborative programs
• Notes: Evotec's multi-target CNS platform includes Nrf2 pathway modulators through academic and pharma partnerships. EVT-501 program and related Nrf2 activators under development through drug discovery collaborations
• Partnerships: Works with major pharma on CNS programs targeting oxidative stress pathways

Academia-Derived Spinouts

Multiple academic groups have spun out companies targeting Keap1-Nrf2 for neurodegeneration:

| Company | Institution Origin | Program Stage |
|---------|-------------------|---------------|
| Keapstone Therapeutics | University of Edinburgh | Preclinical |
| Nrf2 Therapeutics Inc. | Scripps/UC Irvine | Preclinical |
| Orexo | Swedish academic consortium | Phase 1 |

Oxidative Stress Reduction Companies

Cyclo Therapeutics

• Focus: Oxidative stress reduction via wearable drug-device combination
• Lead Candidate: Medical device platform for chronic oxidative stress management
• Mechanism: Transcranial delivery of Nrf2-activating compounds; targets brain oxidative stress reduction
• Indication: Alzheimer's disease
• Stage: Early clinical development
• Notes: Novel drug-device approach combining Nrf2 activation with non-invasive brain delivery. Addresses the CNS penetration challenge that limits most Nrf2 activator therapeutics

Indus Therapeutics

• Focus: Mitochondrial function and Nrf2 pathway targeting
• Lead Program: Mitochondrial-targeted Nrf2 modulators
• Mechanism: Mitochondrial-specific Nrf2 activation; protects neuronal mitochondria from oxidative damage
• Indication: Alzheimer's disease
• Stage: Preclinical
• Notes: Platform focused on targeting Nrf2 specifically to mitochondria. Addresses the energy metabolism deficit observed in AD brains

Pfizer

• Focus: Broad CNS portfolio including oxidative stress approaches
• Programs: Multiple Nrf2-related discovery programs through internal pipeline and partnerships
• Mechanism: Direct Nrf2 activators and upstream modulators of oxidative stress pathways
• Indication: Alzheimer's disease
• Stage: Discovery to Phase 1
• Notes: Significant investment in oxidative stress and neuroprotection approaches for AD. Pfizer Ventures has backed several Nrf2-focused biotech companies[@nrf2_activators]

Epigenetic + Nrf2 Combination Companies

Oryzon Genomics

• Focus: Epigenetic modulation with Nrf2 pathway implications
• Lead Candidate: Iadademstat (ORY-2001) — LSD1 inhibitor with potential Nrf2 cross-talk
• Mechanism: LSD1 (KDM1A) inhibition modulates gene expression; Nrf2 pathway effects through epigenetic regulation of antioxidant genes
• Indication: Alzheimer's disease, Parkinson's disease
• Stage: Phase 2 (AD), Phase 1 (PD)
• Notes: Spanish biotech with dual epigenetic and oxidative stress focus. ORY-2001 targets CNS diseases through modulation of neuroinflammatory and oxidative stress gene networks. LSD1 inhibition upregulates Nrf2 pathway genes as secondary mechanism
• Key Trials: ROSA-AD trial (iadademstat in AD)

Alector

• Focus: Immune dysfunction and neurodegeneration including oxidative stress pathways
• Programs: Multiple programs targeting neuroinflammation and neuronal health
• Mechanism: Immune-based approaches with oxidative stress cross-talk; Nrf2 pathway interactions through immune-neural cross-regulation
• Indication: Alzheimer's disease, Parkinson's disease
• Stage: Phase 2/3
• Notes: While primarily focused on TREM2 and immune therapies, Alector's programs have implications for oxidative stress resolution in neurodegeneration. Their broad neuroimmunology platform intersects with Nrf2 pathway biology

Natural Product and Dietary Supplement Companies

Sulforaphane-Based Programs

Multiple companies and academic groups are developing sulforaphane (broccoli-derived Nrf2 activator) for AD:

| Developer | Product | Stage | Notes |
|-----------|---------|-------|-------|
| Evgen Pharma | SFX-01 (stabilized sulforaphane) | Phase 2 | AD trials in UK; oral formulation |
| Various academic | Broccoli extract / sulforaphane | Phase 2 | Multiple investigator-initiated trials |
| Nutritex | Nrf2-activating botanical | Preclinical | Multi-target antioxidant |

Pipeline Overview

| Company | Drug/Program | Mechanism | Phase | Indication |
|---------|--------------|-----------|-------|-------------|
| Alnylam (Reata) | Bardoxolone methyl | Nrf2 direct activator | Phase 2 | AD |
| Biogen | Dimethyl fumarate | Nrf2 activator | Phase 3 | ALS, Phase 2 AD |
| Oryzon Genomics | Iadademstat | LSD1/Nrf2 cross-talk | Phase 2 | AD |
| Nacuity | NPI-001 | Nrf2 activator | Preclinical | AD |
| Evotec | Keap1 inhibitors | Keap1-Nrf2 disruptors | Discovery | AD |
| Indus Therapeutics | Mito-Nrf2 modulators | Mitochondrial Nrf2 | Preclinical | AD |
| Cyclo Therapeutics | Device+Nrf2 | Oxidative stress reduction | Early clinical | AD |
| Evgen Pharma | SFX-01 | Sulforaphane | Phase 2 | AD |
| Alector | Various | Immune/Nrf2 | Phase 2/3 | AD |

Mechanism of Action

Nrf2 Activation Cascade in AD

The Nrf2-Keap1 pathway operates as follows in Alzheimer's disease:

• Antioxidant enzymes: HO-1, SOD1, SOD2, CAT, GPX
• Detoxification: NQO1, GST, GCL (glutathione synthesis)
• Mitochondrial genes: TFAM, PGC-1α, respiratory chain components
• Chaperones: Hsp70,.sql Hsp90
• Proteasome subunits: PSMB5, PSMD4

Nrf2 in AD Pathophysiology

| AD Feature | Nrf2 Relationship |
|-----------|-------------------|
| Amyloid-beta toxicity | Nrf2 activation reduces Aβ-induced ROS and protects neurons |
| Tau hyperphosphorylation | Nrf2 suppresses kinase activation through redox regulation |
| Neuroinflammation | Nrf2 inhibits NF-κB pathway, reducing microglial activation |
| Mitochondrial dysfunction | Nrf2 upregulates mitochondrial biogenesis genes |
| Synaptic loss | Nrf2 protects synaptic proteins from oxidative damage |
| Cognitive decline | Nrf2 activation correlates with preserved cognition in models |

[@nrf2_neuro]

Therapeutic Challenge: CNS Penetration

The major barrier for Nrf2-targeted AD therapies is limited brain penetration. Most electrophilic Nrf2 activators (bardoxolone, sulforaphane) have suboptimal CNS exposure. Companies are addressing this through:

• Pro-drug strategies: Convert inactive pro-drugs to active Nrf2 activators in the brain
• Nanoparticle delivery: Encapsulate Nrf2 activators for brain-targeted delivery
• Device-assisted delivery: Cyclo Therapeutics' approach of transcranial delivery
• Intrathecal administration: Direct CNS dosing for maximum exposure
• Blood-brain barrier (BBB) shuttles: Engineering Nrf2 activators with BBB-targeting moieties

Cross-Links

• [NRF2-KEAP1 Oxidative Stress Response Pathway](/mechanisms/nrf2-keap1-pathway)
• [NRF2 Signaling in Neurodegeneration](/mechanisms/nrf2-signaling-neurodegeneration)
• [NRF2 Activators for Neuroprotection](/therapeutics/nrf2-activators-neuroprotection)
• [NRF2 Protein](/proteins/nrf2-protein)
• [NRF2 Gene](/genes/nrf2)
• [Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
• [Nrf2-Keap1 Therapeutics Investment Landscape](/investment/nrf2-therapeutics)
• [Alzheimer's Disease Epigenetic and Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Brain Metabolic Dysfunction](/mechanisms/brain-metabolic-dysfunction)

References